

VTI1A Antibody (C-term) Blocking Peptide
Synthetic peptide
Catalog # BP8602b**Specification****VTI1A Antibody (C-term) Blocking Peptide - Product Information**

Primary Accession [Q96AJ9](#)

VTI1A Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 143187

Other Names

Vesicle transport through interaction with t-SNAREs homolog 1A, Vesicle transport v-SNARE protein Vti1-like 2, Vti1-rp2, VTI1A

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP8602b](#) was selected from the C-term region of human VTI1A. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

VTI1A Antibody (C-term) Blocking Peptide - Protein Information

Name VTI1A

Function

V-SNARE that mediates vesicle transport pathways through interactions with t-SNAREs on the target membrane. These interactions are proposed to mediate aspects of the specificity of vesicle trafficking and to promote fusion of the lipid bilayers. Involved in vesicular transport from the late endosomes to the trans-Golgi network. Along with VAMP7, involved in a non-conventional RAB1-dependent traffic route to the cell surface used by KCNIP1 and KCND2. May be involved in increased cytokine secretion associated with cellular senescence.

Cellular Location

Cytoplasmic vesicle. Golgi apparatus membrane; Single-pass type IV membrane protein

VTI1A Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

VTI1A Antibody (C-term) Blocking Peptide - Images

VTI1A Antibody (C-term) Blocking Peptide - Background

V-SNARE that mediates vesicle transport pathways through interactions with t-SNAREs on the target membrane. These interactions are proposed to mediate aspects of the specificity of vesicle trafficking and to promote fusion of the lipid bilayers. It may be concerned with increased secretion of cytokines associated with cellular senescence.

VTI1A Antibody (C-term) Blocking Peptide - References

Tai,G., et.al., Mol. Biol. Cell 15 (9), 4011-4022 (2004)Mallard,F., et.al., J. Cell Biol. 156 (4), 653-664 (2002)